Oncology & Hematology

Backing you throughout the development process

Our understanding of the molecular drivers and immunological mechanisms of disease are stirring seismic shifts in the oncology and hematology treatment landscapes. A continuously evolving environment demands expertise across every stage of product development. For Premier, this is terra firma. Our full-circle perspective supports you with regulatory consulting, nonclinical services, adaptive and biomarker-driven trial designs, connections to patient advocacy groups, clinical trial delivery, and proven strategies for engaging patients and families throughout the development process.

Unmatched expertise for maneuvering through complexity

With a track record of nearly 200 oncology and hematology projects over the past five years — including multiple rare cancer, pediatric, and cell and gene therapy studies — we invest our experience in your success and continue to expand our capabilities.

Enlarge Image

×

From breakthrough science to breakthrough therapies

Oncology and hematology drug development has been transformed by immuno-oncology, emerging therapies, and the evolution of precision medicine. As treatments become more complex, the need for smarter product development and clinical trial management grows. Premier provides a holistic approach to delivery to enhance the likelihood of success, from concept to commercialization.

• Experience across the spectrum of treatment modalities, including cell and gene therapies, monoclonal antibodies, targeted immunotherapies, metabolic pathway inhibitors, and growth pathway inhibitors.
• Innovative study designs, including master protocols or platform trials, biomarker-guided studies, and adaptive designs for both early- and late-phase trials.
• A track record of recruiting and engaging difficult-to-find patient populations for rare, ultra-rare, and pediatric oncology and hematology indications.
• Medical device expertise that spans more than 20 years and includes companion diagnostics and liquid biopsies for early cancer detection, patient stratification, treatment eligibility, and response monitoring.
• Collaborative strategic partnerships with biodatabanks, multiomic reference laboratories, and leaders in advanced computational modeling and simulation to accelerate development and minimize risk.